


RealRate

PHARMACEUTICAL 2022

Tyra Biosciences Inc. Rank 39 of 475





PHARMACEUTICAL 2022



Tyra Biosciences Inc. Rank 39 of 475

The relative strengths and weaknesses of Tyra Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tyra Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 171% points. The greatest weakness of Tyra Biosciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 421% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	304,057
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,616
Liabilities, Non-Current	1,348
Other Assets	1,617
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-6.0
Property and Equipment	1,027
Research and Development	20,636
Revenues	0
Selling, General and Administrative Expense	5,652

Output Variable	Value in 1000 USD
Assets	306,701
Liabilities	4,964
Expenses	26,288
Stockholders Equity	301,737
Net Income	-26,294
Comprehensive Net Income	-26,294
Economic Capital Ratio	144%